13F HOLDINGS REPORT
ARCH Venture Management, LLC
Quarter ended Q2 2024 · Filed August 14, 2024 · Accession 0001012975-24-000339
Total Value
$266.0M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BEAM THERAPEUTICS INC. | BEAM | 5,443,039 | $127.5M | 47.94% |
| 2 | RAPPORT THERAPEUTICS, INC. | RAPP | 3,728,738 | $86.7M | 32.60% |
| 3 | ERASCA, INC. | ERAS | 11,055,554 | $26.1M | 9.81% |
| 4 | VERVE THERAPEUTICS, INC. | 92539P101 | 2,008,809 | $9.8M | 3.69% |
| 5 | GOSSAMER BIO, INC. | GOSS | 8,055,916 | $7.3M | 2.73% |
| 6 | Q32 BIO INC. | QTTB | 320,482 | $5.8M | 2.16% |
| 7 | UNITY BIOTECHNOLOGY, INC. | UNTCW | 1,004,817 | $1.4M | 0.51% |
| 8 | SINGULAR GENOMICS SYSTEMS, INC. | 82933R308 | 126,630 | $1.1M | 0.40% |
| 9 | CERO THERAPEUTICS HOLDINGS, INC. | 71902K105 | 1,444,296 | $431,845 | 0.16% |